Insights On Upstream Manufacturing

  1. The Scale-Up Of A Transient rAAV8 Production Process 6/18/2026

    New approaches to suspension cell culture and process scaling enable consistent, high-titer rAAV production. Gain insight into a clearer path to scalable manufacturing for gene therapy pipelines.

  2. Elevate Your Protein Production With SynWeave™ 6/15/2026

    Sunit Maity, Ph.D., Senior GM – Biologics Services, introduces an advanced platform that combines state-of-the-art cell line and transposon-based technologies from ExcellGene.

  3. Effects Of Sequence Fidelity On Cloning Efficiency 6/15/2026

    dsDNA fragments speed up cloning but introduce variability that can affect results. Comparing fragment fidelity, efficiency, and design considerations helps researchers choose the right approach.

  4. Scalable rAAV9 Production Using Advanced Cell Lines And Bioreactors 6/15/2026

    Progress in gene therapy manufacturing is being driven by improved cell line performance and scalable bioprocessing. See how high-density growth helps streamline development to larger-scale production.

  5. Develop Clones In Just 9 Weeks From Transfection With Up To 4X Titer 6/15/2026

    Transposon-based cell line development cuts timelines by 10 weeks and hits titers of 4.8 g/L in 17 days. See how SynWeave delivers measurable biologics manufacturing gains.

  6. Direct Scale Up From Clone To 2K GMP Batches 6/15/2026

    N-1 perfusion technology increased antibody titers 1.5–4.5x over conventional fed-batch methods. See how high seed density and media blending cut costs and maximize suite utilization.

  7. Leveraging Integrated Media Services For Speed And Efficiency 6/12/2026

    Uncertainty in media stability can limit efficiency and scalability in biologics manufacturing. See how a data-driven approach enables more predictable planning and reduces operational strain.

  8. Enabling Clinical-Grade Automated Manufacturing Of γδ T Cells 6/12/2026

    Explore smarter approaches to γδ T cell manufacturing, including scalable expansion, efficient transduction, and streamlined analytics, as well as how to build workflows that support validation.

  9. Establishing The First Chinese Haplobank Of Clinical-Grade hiPSCs 6/11/2026

    Learn how automated, closed workflows and GMP-ready infrastructure are advancing pluripotent stem cell development from scalable expansion and differentiation to building regional capacity.

  10. Achieving Clinical Quality For Human iPSC Generation And Expansion 6/11/2026

    Gain practical insight into building scalable stem cell manufacturing processes while maintaining consistency and quality across workflows, as well as in-depth guidance to support your strategy.